Abu-Abaa Mohammad, Hassan Mohamed, Mousa Aliaa, Arshad Hassaan, Shah Samir
Internal Medicine, Capital Health Regional Medical Center, Trenton, USA.
Cardiology, Capital Health Regional Medical Center, Trenton, USA.
Cureus. 2023 May 16;15(5):e39072. doi: 10.7759/cureus.39072. eCollection 2023 May.
Heparin is a preferred initial anticoagulant in patients with new-onset atrial fibrillation (AF). Despite continuous debate about the risk, there has been a concern about heparin-induced hemorrhagic pericarditis and cardiac tamponade. We present a case of a new onset atrial fibrillation (AF) in a patient with renal impairment and evidence of pericardial effusion complicated by hemopericardium development after starting anticoagulation. Although the risk of hemorrhagic conversion of uremic pericarditis induced by heparin in ESRD patients with new onset AF was suggested in the literature, this case raises the possibility of a similar complication in dialysis-associated pericarditis. Therefore, we aim to heighten alertness regarding this potential complication of a commonly used medication in clinical practice. We also aim to review the current anticoagulation recommendations in this setting.
肝素是新发房颤(AF)患者首选的初始抗凝剂。尽管关于风险的争论不断,但人们一直担心肝素诱导的出血性心包炎和心脏压塞。我们报告一例肾功能不全患者新发房颤(AF),且有证据表明在开始抗凝治疗后出现心包积液并并发血心包。虽然文献中提示新发房颤的终末期肾病(ESRD)患者肝素诱导尿毒症心包炎出血转化的风险,但该病例增加了透析相关性心包炎出现类似并发症的可能性。因此,我们旨在提高临床实践中对这种常用药物潜在并发症的警惕性。我们还旨在回顾这种情况下目前的抗凝建议。